None listed
Conditions
Interventions
None listed
Sponsors
Daiichi-Sankyo Korea
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males or females aged = 65 years with a diagnosis of dyslipidemia 2. Patients who were prescribed Mevalotin® in the judgment of their physicians, or who started receiving Mevalotin® tab. within 6 weeks from enrollment in this observational study 3. Voluntary written consent to participation in this observational study by the patients or their representatives
Exclusion criteria
Exclusion criteria: 1. Subjects who were enrolled even though they violated the prior study's inclusion/exclusion criteria 2. Subjects who took another statin drug before participating in prior studies. 3. Subjects who took pravastatin 5 mg or 10 mg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of Adverse Drug Reactions | — |
Secondary
| Measure | Time frame |
|---|---|
| The achivement rate of the LDL-C goal defined in the Korean Guidelines for Management of Dyslipidemia 4th and 5th edition after the administration of Mevalotin® tab. for 24 weeks | — |
Countries
Korea, Republic of
Contacts
Public ContactYoungmi Lee
Daiichi-Sankyo Korea
Outcome results
None listed